glp-1 weight loss drug news november 2025 Poll: 1 in 8 Adults Say They Are Currently Taking a for Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford GLP-1 and Health: Beyond Weight

Important Safety Information for Soliqua 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL What is the most important information I should know about Soliqua 100/33

Novo Nordisk spent a billion dollars on marketing in 2021-2022 and took 239,000 doctors to dinner and lunch, essentially educating the entire market on a critical concept: weight management is a physiological, hormonally-driven process, not about willpower

[DOI] [PubMed] [Google Scholar] 392.Pyke C., Heller R.S., Kirk R.K., Orskov C., Reedtz-Runge S., Kaastrup P

It should also be recognized that the risk for emesis and aspiration during emergence is also a real concern even with gastric decompression if the patient has residual solid gastric contents